NCT04397523

Efficacy and Safety of COVID-19 Convalescent Plasma

Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (actual)
• Sponsor: Institute for Transfusion Medicine of RNM · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

Detailed description

There are currently no proven therapeutic options for coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19. Experience from prior outbreaks with other coronaviruses, such as SARS-CoV-1, MERS and H1N1 shows that convalescent plasma can be effective. Convalescent plasma will be obtained by plasmapheresis or regular whole blood donation in subjects who recovered from COVID-19 and who are otherwise eligible for donation according to the Institutional protocol. Recipients will be COVID-19 patients requiring hospitalization. A blood-type matched transfusion of convalescent plasma will be infused and recipients will be followed up.

Conditions

• Convalescent Plasma
• COVID-19
• SARS-CoV 2

Interventions

Type	Name	Description
BIOLOGICAL	anti-SARS-CoV-2 convalescent plasma	Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

Timeline

• Start date: 2020-04-30
• Primary completion: 2021-05-10
• Completion: 2021-05-10
• First posted: 2020-05-21
• Last updated: 2024-05-28
• Results posted: 2024-05-28

Locations

1 site across 1 country: North Macedonia